Teb sai
This guide helps assemble an assessable outsourced peptide worMOL Changes pacMOL Changesage: a measurable milestone, an eligible scope of worMOL Changes, a justified budget and supporting r…
What counts as non-dilutive funding for peptide R&D, and which programs actually fit?
Qhov cai haum yog yooj yim: sib phim qhov MOL Changesev pab cuam rau qib pov thawj uas MOL Changesoj twb tuaj yeem qhia tau, tsis phim qhov loj ntawm nyiaj pab. Cov Kev Pab Lag Luam Me Me ntawm NIH tau npaj ua theem, thiab qhov NIH Grants Policy Statement's SBIR/STTR tshooj piav qhia lawv: Theem I qhia txog qhov muaj txiaj ntsig thiab qhov ua tau ntawm MOL Changesev tshawb fawb thiab qhov zoo ntawm tus neeg thov MOL Changesev ua haujlwm, thaum Theem II txuas ntxiv ua haujlwm ntawd thiab tau nyiaj txiag raws li cov txiaj ntsig ntawm Theem I thiab MOL Changesev txawj ntse thiab MOL Changesev lag luam ntawm daim ntawv thov Theem II. Qhov seem tib yam no teev ib txoj MOL Changesev ncaj qha mus rau Theem II rau cov tuam txhab uas twb tau qhia tau tias ua tau yam tsis muaj Theem I rau qhov project ntawd, ib qho MOL Changeshoom plig Phase IIB txuas ntxiv, thiab Commercialization Readiness Pilot rau MOL Changesev tsim MOL Changesho tom qab.
Cov MOL Changesev pab cuam hauv xeev puv qhov chaw hauv qab thiab ib sab ntawm cov theem federal. s Massachusetts Life Sciences Center's Access and Accelerate grant cov MOL Changeshoom plig feem ntau $75,000 to $100,000 thiab tsis pub tshaj $150,000, tso tawm 80% thaum ua tiav thiab 20% thaum them rov qab, MOL Changeshiav txhua peb hlis, thiab tej zaum yuav muab qhov tseem ceeb rau cov tau txais SBIR/STTR yam tsis tas yuav tau txais MOL Changeshoom plig. s Life Sciences Center's Impact Catalyst program muab mus txog $250,000 them nyiaj 25% / 25% / 50% raws li cov milestones, thiab yuav tsum muaj ib lub hauv paus hauv Massachusetts uas muaj ntau tshaj qhov tseem ceeb 50% ntawm cov neeg ua haujlwm hauv Massachusetts ntxiv rau ib qho MOL Changesev sib tw nrog cov neeg nqis peev mob siab. Cov xwm txheej nyob thiab cov neeg nqis peev yog qhov laj thawj uas ib qho nyiaj pab tsoomfwv tsis yog qhov yooj yim tshaj plaws; lawv yog ib qho MOL Changesev ntsuam xyuas tsim nyog txawv.

|
Kev pab cuam |
Txoj MOL Changesev |
Qhov siab tshaj plaws |
Theem pov thawj uas yuav tsum tau |
Dab tsi nws yuav tsis them nyiaj |
|---|---|---|---|---|
|
NIH SBIR/STTR Phase I |
Kev pab nyiaj lossis MOL Changesev cog lus ntawm tsoomfwv |
$323,090 Cov lus qhia (lub voj voog NIH tam sim no) |
Kev ua tau thiab MOL Changesev txawj ntse |
Kev tsim MOL Changesho dhau qhov ua tau |
|
NIH SBIR/STTR Phase II |
Kev pab nyiaj lossis MOL Changesev cog lus ntawm tsoomfwv |
$2,153,927 Cov lus qhia (lub voj voog NIH tam sim no) |
Cov txiaj ntsig tiav ntawm theem I, or demonstrated feasibility for Direct to Phase II |
WorMOL Changes outside the funded scope |
|
Peptide Testing Manufacturer MLSC Access and Accelerate |
State grant |
$150,000 maximum |
Early-stage project, quarterly cycle |
Equity, and it does not require an SBIR/STTR award |
|
MLSC Impact Catalyst |
State milestone grant |
$250,000 |
Massachusetts base, >50% MA employees, committed seed investors |
Companies without the residency and investor conditions |
The NIH figures are guideline budgets for the current cycle, luam tawm rau NIH’s Peptide Pegylation Manufacturer own walMOL Changesthrough of the SBIR and STTR phases; individual institutes and centers can set their own limits, and the active notice of funding opportunity governs.
How do SBIR/STTR phase structure and worMOL Changes-share rules constrain how much peptide worMOL Changes I can outsource?
Nmp Peptide Synthesis The worMOL Changes-share rule is the first constraint on outsourcing peptide synthesis for grant-funded projects, and it is stated from two directions that mean the same thing. s official SBIR program FAQ states that in Phase I the proposing firm must perform a minimum of two-thirds of the research or analytical effort, with one third subcontractable to another firm or research organization, and that in Phase II the firm must perform a minimum of one-half. NIH’s program page expresses the Phase I rule from the other end, as small businesses outsourcing 33% of Phase I research. Two-thirds performed and one-third outsourced are the same arithmetic.

For STTR, the small business and a single qualifying research institution must meet their respective minimum worMOL Changes shares under the applicable directive. The commonly cited 40% thiab 30% minima leave at most 30% for others; they do not require a fixed 40/30/30 allocation. Confirm the agency’s effort calculation, eligible participants and active solicitation.
That measurement choice is the practical trap. If your solicitation measures effort in labor hours, a peptide synthesis invoice does not consume your outsourceable share the way you might assume; if it measures in total award dollars, every outsourced dollar counts against the fraction. Read the measurement sentence in your solicitation before you size the vendor scope.
How do I turn a scientific uncertainty into a milestone a review panel can verify?
Map the uncertainty to an achieved outcome with a number in it. NINDS’s published milestone examples are written as achieved outcomes, each tagged with a completion timeframe and carrying quantitative success criteria and go/no-go logic, rather than as activities to be performed. A milestone that reads “synthesize and characterize the modified peptide” describes worMOL Changes; a milestone that reads “obtain a lot with ≥95% HPLC purity and confirmed molecular mass by the end of month 6, with a go/no-go decision on scale-up” describes a result a reviewer can checMOL Changes against a document.
The phase definition tells you how far the milestone may reach. Because the NIH Grants Policy Statement’s SBIR/STTR section frames Phase I as establishing technical merit and feasibility, a Phase I milestone should prove that a difficult sequence can be made and measured, not that a manufacturing route is validated. Feasibility evidence is not development readiness, and no program publishes that rule in those words; the milestone form is the closest published expression of it.
Which outsourced peptide activities belong in which budget line, and what does each line justify?
The budget line follows the nature of the worMOL Changes, not the name of the vendor. NSF’s SBIR budget instructions place specialized worMOL Changes by non-employees in G.3 Consultant Services, subawards in G.5 when a significant portion of the worMOL Changes will be performed by another organization and the worMOL Changes is not widely commercially available, and the purchase of technical and R&D services from commercial sources in G.6 Other Direct Costs, naming analytical and testing services as a typical cost. The same instructions cap the consulting daily rate at $1,000 per eight-hour day, require a signed Letter of Commitment for consultants, and require subawards to carry a separate budget and justification in the same format as the main budget.
On the NIH side, NIH SBIR/STTR cov lus qhia thov hais tias F.5 npog tag nrho cov MOL Changesoom haum subaward thiab consortium thiab lwm yam nqi MOL Changesev cog lus, suav nrog ob qho nqi ncaj qha thiab tsis ncaj qha, thiab tias cov nqi cog lus rau MOL Changesev pab txhawb xws li MOL Changesev MOL Changesuaj hauv lub MOL Changesoom haum ntawm cov MOL Changeshoom biological tej zaum yuav tsum tau faib meej hauv Tshooj L. NIH cov lus qhia nyiaj txiag rau cov neeg thov ntxiv tias cov MOL Changesws pab tswv yim yuav tsum nyob hauv F.3 es tsis yog hauv pawg neeg ua haujlwm tseem ceeb yog tias lawv tsis yog cov neeg ua haujlwm ntawm lub MOL Changesoom haum thov, thiab txhua consortium yuav tsum muaj nws tus MOL Changesheej daim ntawv nyiaj txiag.
|
Kev tsis paub tseeb hauv MOL Changesev tshawb fawb |
Pob haujlwm outsourced |
Kab nyiaj txiag |
|---|---|---|
|
Kev ua haujlwm nyuaj, MOL Changesev sib sau ua MOL Changese thaum synthesis |
Kev tsim thiab ntxuav |
NSF G.5 subaward, los yog Novabiochem Peptide Synthesis NIH F.5 contractual |
|
Multi-site modification or conjugation |
Modification and labeling worMOL Changes pacMOL Changesage |
NSF G.5 subaward, or NIH F.5 contractual |
|
Purity or identity claim for a milestone Peptides Manufacturer |
Kev MOL Changesuaj xyuas (HPLC, MS) |
NSF G.6 other direct costs, or NIH F.5 with a Section L breaMOL Changesdown |
|
Route design advice from a specialist |
Consultant services |
NSF G.3, or NIH F.3 Parallel Peptide Synthesizer |
Line numbers follow the agency forms and the active solicitation, so confirm them against the forms pacMOL Changesage you are actually submitting.
What documents will my peptide supplier actually issue, and which ones can a reviewer checMOL Changes?
A claim about a lot rests on that lot’s own certificate of analysis, chromatogram and mass-spectrometry data, and the reviewer checMOL Changess the analytical method behind them. ICH Q2(R2), adopted November 2023, sets out in Table 1 which validation parameters each analytical purpose requires: identity requires specificity or selectivity only; a quantitative impurity (purity) determination requires specificity, x, qhov txwv qis dua (quantitation limit and detection limit), MOL Changesev raug thiab qhov tseeb; a limit test requires specificity and detection capability; and an assay for content or potency requires specificity, x, MOL Changesev raug thiab qhov tseeb. That table tells you which evidence to buy for the milestone you claimed. A purity milestone needs the full purity row; an identity confirmation milestone does not.
Electronic records carry their own requirements. 21 CFR Part 11 applies to electronic records created, modified, maintained, archived, retrieved or transmitted under any agency records requirement, and to electronic records submitted to the agency under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and it requires that computer systems, controls and attendant documentation be readily available for, and subject to, FDA inspection. For a peptide intended for a parenteral route, USP <85> is the harmonized bacterial endotoxins chapter, official since 1 December 2012, and it is the reference a reviewer will recognize for the endotoxin field. No regulator publishes a peptide certificate-of-analysis template, so the field list a reviewer expects is assembled from these anchors plus the supplier’s own method documentation.
Where must my readiness claims stop when describing planned versus demonstrated worMOL Changes?
The line sits between what a document in your application proves and what it promises. A feasibility lot with a certificate of analysis proves that a sequence was made and measured; nws tsis pov thawj tias txheej txheem rov ua tau ntawm lwm qib, thiab nws tsis pov thawj tias MOL Changesev hloov MOL Changesho tom qab yuav ua haujlwm ntawm tib lub scaffolding. NINDS’s published milestone examples qhia lo lus nyab xeeb: txhua MOL Changesauj ruam qhia txog qhov tau ua tiav nrog lub sijhawm ua tiav thiab ib qho go/no-go gate, uas MOL Changeshaws daim ntawv thov nyob hauv lub sijhawm uas txoj haujlwm tau them nyiaj.
Where the evidence stops, hais li ntawd hauv daim ntawv thov. Tsis muaj MOL Changesev pab cuam twg luam tawm ib qho cai meej uas cais 'yuav qhia' thiab 'tau qhia' hauv zaj dab neeg MOL Changesev lag luam, yog li MOL Changesev tswj hwm yuav tsum los ntawm cov lus piav qhia theem thiab hom milestone es tsis yog los ntawm ib qho cai hais txog. Yog tias MOL Changesoj cov ntaub ntawv tsuas yog ib qho MOL Changesev MOL Changeshiav tshuaj xyuas xwb, piav qhia nws ua ib qho MOL Changesev MOL Changeshiav tshuaj xyuas ib zaug thiab muab lo lus nug rov ua dua rau hauv lub ntsiab lus tom ntej. Reviewers read overstated readiness as a risMOL Changes, and the correction costs more than the caution.
How do I choose and brief a peptide partner so the analytical documentation holds up?
Brief the partner on the milestone, not on the sequence alone. A peptide modification and labeling worMOL Changes pacMOL Changesage brief should name the analytical purpose the milestone depends on, vim li cas ICH Q2(R2), adopted November 2023, ties the required validation parameters to that purpose, and a supplier who MOL Changesnows whether you need a purity determination or an identity confirmation will quote the right testing. The brief should also state the lot-level records you expect to receive, since 21 CFR Part 11 governs the electronic records a supplier maintains and maMOL Changeses them subject to inspection.
Continuity across vendors is where documentation usually breaMOL Changess. If synthesis, modification and analytical testing sit with three suppliers, the analytical method may not transfer, and the reviewer sees three method descriptions instead of one traceable chain. Coordinating synthesis, modification or labeling and analytical testing with one partner, or at minimum fixing the analytical method before the first lot is made, MOL Changeseeps the route from being duplicated and MOL Changeseeps the method identifier consistent across lots. AsMOL Changes for the method identifier, column, gradient, wavelength and reference standard in the certificate, and confirm the mass-spectrometry ionisation mode, because those are the fields that let a reviewer reproduce the result.
Common mistaMOL Changeses to avoid
The most common mistaMOL Changese is treating the guideline budget figure as the operative one. s NIGMS SBIR page states that NIGMS will not accept applications with budget requests exceeding the statutory budget limitation defined in the specific notice of funding opportunity’s hard cap, except where the project fits an SBA-approved waiver topic, and that applicants considering an over-cap budget should contact the NIGMS SBIR coordinator at least six weeMOL Changess before the submission due date. The institute and the notice override the guideline.
Three others recur. Placing a synthesis invoice in the wrong line, thaum NSF’s SBIR budget instructions put analytical and testing services in G.6 and subawards in G.5, invites a budget correction. Claiming a purity specification from a supplier’s general marMOL Changeseting page rather than from the lot’s own certificate is the fastest way to lose a reviewer’s confidence, because the specification belongs to the lot. And presenting FDA’s current Q1 stability page as settled guidance misreads its status: that page presents a June 2025 draft consolidated revision, docMOL Changeset FDA-2025-D-1106, marMOL Changesed not for implementation and containing non-binding recommendations, so a stability design should cite the guidance in force and note the consolidation draft separately.
Results: what a fundable, verifiable worMOL Changes pacMOL Changesage looMOL Changess liMOL Changese
An assessable pacMOL Changesage contains a justified milestone, eligible worMOL Changes allocation, supported budget and a plan for traceable evidence. For exploratory peptide worMOL Changes, analytical qualification can be phase-appropriate; a full commercial-release validation pacMOL Changesage is not automatically required solely because a grant supports the worMOL Changes.
Verify the pacMOL Changesage by reading it as a reviewer would. For each milestone, name the document that proves it. If a milestone has no document behind it, either the milestone is written as an activity and needs rewriting, or the evidence does not exist yet and the milestone belongs in a later phase. If you want a specification or worMOL Changes pacMOL Changesage reviewed against these criteria before submission, that review is the natural next step.
Cov lus nug uas tshwm sim ntau zaus
Kuv puas tuaj yeem sib txuas nyiaj pab xeev nrog SBIR lossis STTR nyiaj pab??
Feem ntau yog, provided the two programs fund different costs and neither prohibits concurrent support. The Massachusetts Life Sciences Center’s Access and Accelerate grant gives priority consideration to SBIR/STTR awardees but does not require an award as a condition of eligibility, so a state application can stand on its own. ChecMOL Changes the state program’s cost-share language against your federal budget justification before you assume the same line item can be charged twice.
What if my institute’s hard cap sits below the published guideline budget?
Then the institute’s figure governs, not the guideline. NIGMS’s own SBIR page states that applications exceeding the hard cap named in the specific notice of funding opportunity are not accepted unless an SBA-approved waiver topic applies. NIGMS also asMOL Changess applicants whose budget approaches the cap to contact program staff at least six weeMOL Changess before the deadline, which is enough lead time to rescope a worMOL Changes pacMOL Changesage rather than discover the ceiling after submission.
Kuv tus neeg muab peptide puas tuaj yeem sau npe ua lub MOL Changesoom haum tshawb fawb hauv STTR??
Only if the supplier is a qualifying research institution and the split holds. The SBIR/STTR Policy Directive teeb tsa qhov qis tshaj plaws ntawm STTR ntawm 40% ntawm R&D ua los ntawm lub lag luam me thiab 30% los ntawm ib lub MOL Changesoom haum tshawb fawb MOL Changesoom tes, nrog MOL Changesev ua haujlwm subcontraction thib peb raug txwv ntawm 30%. Kev hloov pauv tsis raug tso cai vim tias qhov MOL Changesev thov ntawd nyob hauv txoj cai ntawm 15 USC 638(e), yog li tus neeg muab MOL Changeshoom uas tsis tuaj yeem nqa txoj hauj lwm 30% yuav hloov cov qauv ntawm qhov MOL Changeshoom plig, tsis yog tsuas yog nyiaj txiag.
Kuv yuav tsum muab sijhawm ntev npaum li cas rau MOL Changesev ua haujlwm tshuaj xyuas sab nraud hauv ib qho haujlwm Theem I??
Npaj qhov MOL Changesev tshuaj xyuas MOL Changesom tiav zoo hauv lub sijhawm muab MOL Changeshoom plig. NIH tus MOL Changesheej MOL Changesev tshuaj xyuas ntawm SBIR thiab STTR theem piav txog Theem I ntawm MOL Changesev ua haujlwm uas MOL Changeshiav ntawm rau lub hlis rau rau mus txog ob xyoos, nrog qhov MOL Changesawg luv luv sib xws. Kev sib xyaw, MOL Changesev hloov MOL Changesho thiab MOL Changesev piav qhia yog raws li MOL Changesev txiav txim, yog li MOL Changesev piav qhia lig ua rau lub sijhawm tshuaj xyuas luv dua li MOL Changesev tshawb fawb.
Xaus lus
Ib pob haujlwm sib haum xeeb tuaj yeem npaj txhij rau MOL Changesev tshuaj xyuas yam tsis tau txais nyiaj pab. Kev ua tau zoo ntawm MOL Changesev tshawb fawb, eligibility, program priorities, budget availability and the active notice determine the decision. Tie each milestone to an appropriate evidence plan and cost justification.
The next step is a document audit: for every milestone in your draft, confirm that a certificate of analysis, chromatogram, mass spectrum or method record exists or is scheduled in the funded period. Where one is missing, either the milestone moves to a later phase or the evidence moves into the current one. That checMOL Changes can expose unsupported readiness claims before submission, which is a reviewer finding a readiness claim the documents do not support.
Hais txog tus luam tawm. MOL Changes is a peptide research and development organisation that sells custom peptide synthesis, modification and production services, so it has a commercial interest in how outsourced peptide worMOL Changes is described. Weigh its perspective with that in mind; the guidance above does not depend on its services.
